Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 777

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 777
---
 |     |     |                 1,929 |     |     | —                 |     |     | —                 |     |     |                 1,929 |     |     |          58.00 |
| Issuance of Preferred SeriesC-2Agent Warrants |     |     |                   219 |     |     | —                 |     |     | —                 |     |     |                   219 |     |     |          60.70 |
| Issuance of Preferred SeriesC-3Agent Warrants |     |     |                   296 |     |     | —                 |     |     | —                 |     |     |                   296 |     |     |          57.50 |
|                                               |     |     |                 2,444 |     |     | —                 |     |     | —                 |     |     |                 2,444 |     |     |                |

The following table summarizes the Company’s outstanding Series C Agent Warrants as of June 30, 2024:

| Series C Agent Warrants |     | Number |       |     | Conversionprice$ |       |     | Number ofconversionshares(in thousands) |    |     | Cumulativecommonstockdividends(in thousands) |    |
| Series 1                |     |        | 1,929 |     |                  | 58.00 |     |                                         | 33 |     |                                              | 23 |
| Series 2                |     |        |   219 |     |                  | 60.70 |     |                                         |  4 |     |                                              |  3 |
| Series 3                |     |        |   296 |     |                  | 57.50 |     |                                         |  5 |     |                                              |  4 |
|                         |     |        | 2,444 |     |                  |       |     |                                         | 42 |     |                                              | 30 |

The Series C Agent Warrants expired unexercised subsequent to June 30, 2024, on August 19, 2024.

9. Income taxes

For the years ended June 30, 2024, and 2023, the Company did not record a provision for deferred income taxes due to a full valuation allowance against the deferred tax assets.

Significant components of the Company’s deferred tax assets and deferred tax liabilities are shown below:

|